Torsdag 19 November | 08:20:59 Europe / Stockholm
Est. tid*
2027-05-11 N/A Årsstämma
2027-02-11 08:00 Bokslutskommuniké 2026
2026-11-11 - Kvartalsrapport 2026-Q3
2026-08-20 - Kvartalsrapport 2026-Q2
2026-05-11 - X-dag ordinarie utdelning IMMU 0.00 SEK
2026-05-08 - Årsstämma
2026-05-08 - Kvartalsrapport 2026-Q1
2026-02-11 - Bokslutskommuniké 2025
2025-12-16 - Extra Bolagsstämma 2025
2025-11-13 - Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-07 - X-dag ordinarie utdelning IMMU 0.00 SEK
2025-05-06 - Årsstämma
2025-05-06 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-06-03 - Split IMMU 20:1
2024-05-20 - X-dag ordinarie utdelning IMMU 0.00 SEK
2024-05-17 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-12-13 - Extra Bolagsstämma 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-15 - X-dag ordinarie utdelning IMMU 0.00 SEK
2023-05-12 - Årsstämma
2023-05-12 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-18 - Extra Bolagsstämma 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-11 - X-dag ordinarie utdelning IMMU 0.00 SEK
2022-05-10 - Årsstämma
2022-05-10 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-05 - X-dag ordinarie utdelning IMMU 0.00 SEK
2021-05-04 - Årsstämma
2021-05-04 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2021-01-22 - Extra Bolagsstämma 2021
2020-12-18 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-04-29 - X-dag ordinarie utdelning IMMU 0.00 SEK
2020-04-28 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-18 - Bokslutskommuniké 2019
2019-11-06 - Kvartalsrapport 2019-Q3
2019-08-20 - Kvartalsrapport 2019-Q2
2019-04-26 - X-dag ordinarie utdelning IMMU 0.00 SEK
2019-04-25 - Årsstämma
2019-04-25 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018
2018-11-07 - Kvartalsrapport 2018-Q3
2018-08-17 - Kvartalsrapport 2018-Q2
2018-05-04 - Kvartalsrapport 2018-Q1
2018-04-26 - X-dag ordinarie utdelning IMMU 0.00 SEK
2018-04-25 - Årsstämma
2018-02-16 - Bokslutskommuniké 2017
2017-12-04 - Extra Bolagsstämma 2017
2017-11-17 - Kvartalsrapport 2017-Q3
2017-08-18 - Kvartalsrapport 2017-Q2
2017-05-19 - Kvartalsrapport 2017-Q1
2017-04-27 - X-dag ordinarie utdelning IMMU 0.00 SEK
2017-04-26 - Årsstämma
2017-02-17 - Bokslutskommuniké 2016
2016-05-20 - Kvartalsrapport 2016-Q3
2016-02-19 - Kvartalsrapport 2016-Q2
2015-12-03 - Årsstämma
2015-09-18 - Bokslutskommuniké 2015
2015-05-21 - Kvartalsrapport 2015-Q3
2015-02-20 - Kvartalsrapport 2015-Q2
2014-12-04 - X-dag ordinarie utdelning IMMU 0.00 SEK
2014-12-03 - Årsstämma
2014-11-18 - Kvartalsrapport 2015-Q1
2014-09-17 - Bokslutskommuniké 2014
2014-05-07 - Kvartalsrapport 2014-Q3
2014-02-18 - Kvartalsrapport 2014-Q2
2013-12-04 - X-dag ordinarie utdelning IMMU 0.00 SEK
2013-12-03 - Årsstämma
2013-12-03 - Kvartalsrapport 2014-Q1
2013-09-10 - Bokslutskommuniké 2013
LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Mendus är verksamt inom medicinteknik. Bolaget producerar terapeutiska vacciner som används inom området för onkologi. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet med fokus på behandling av allvarliga tumörer. Exempel på sjukdomar som produkterna används mot innefattar njur- och levercancer. Störst verksamhet återfinns inom den nordiska marknaden. Mendus grundades år 2002 och har sitt huvudkontor i Stockholm.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Mendus announces initial immunological data from CADENCE and VITAL-CML indicating vididencel improves immune competence across indications

2026-11-11 08:00:00
  • Vididencel-induced immune responses activate multiple compartments of the immune system based on initial samples from the ongoing CADENCE and VITAL-CML trials
  • The data are consistent with earlier observations from the completed ADVANCE II and ALISON trials, indicating vididencel improves immune competence across indications

Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced the initial immune data based on samples collected in the ongoing CADENCE and VITAL-CML trials. The data indicate vididencel improves immune competence across indications.

“We are encouraged by the initial immunological data collected from the ongoing CADENCE and VITAL-CML trials, which confirm the observations from the completed ADVANCE II trial in acute myeloid leukemia and ALISON trial in ovarian cancer”, said Mendus CEO Erik Manting. “The data suggests that vididencel modulates multiple compartments of the immune system and improves immune competence, which may be relevant to control residual disease. Longer-term follow-up of the ongoing trials will be required to assess the effect of vididencel treatment on disease, with multiple read-outs expected in 2027.”

The AMLM22-CADENCE (CADENCE) trial (N=40) is an ongoing randomized Phase 2b combination trial with oral azacitidine (oral-Aza), an approved drug for maintenance therapy following high-intensity chemotherapy in newly diagnosed acute myeloid leukemia (AML). Analysis of samples collected from 13 patients (7 in the vididencel+oral-Aza and 6 in the oral-Aza arm) revealed that patients treated with vididencel had a better preserved CD8+ effector/CD4+ helper T cell ratio and demonstrated a downward trend in regulatory (suppressor) T cells. Levels of LAG3+ (exhausted) T cells also went down, whereas there was an upward trend in memory B cells and memory NK cells, which have been associated with improved survival in AML. Combined, the data confirm that vididencel improves immune competence in a randomized trial setting. The CADENCE trial data will be presented by the principal investigator, Dr Victoria Ling, during the Scientific Meeting of the Australasian Leukaemia and Lymphoma Group (ALLG) held November 10-13. A first read-out (N=20) to determine whether vididencel added to oral-Aza in AML maintenance reduces risk of disease progression compared to oral-Aza alone is expected H1 2027.

The VITAL-CML Phase 1b trial (N=24) studies vididencel in patients with a suboptimal response to standard-of-care treatment with tyrosine kinase inhibitors (TKIs). Immune data based on samples collected from 7 evaluable patients showed an initial encouraging trend in select immunological markers for regulatory T cells, NK cells and specific T cell subsets. A sustained deepening of molecular disease based on BCR::ABL1 levels in the blood was not yet apparent in in the trajectories shown (~8–18 weeks, unequal follow-up), with one patient showing a trend toward deep molecular response (DMR) in the last sample collected at week 18. Longer follow-up will be needed to establish a potential immune effect on molecular disease following vididencel treatment in this specific patient population. Topline data are expected in mid-2027. Mendus had previously communicated successful completion of the safety and tolerability stage of the VITAL-CML trial and start of preparations for the VITAL-TFR2 trial that will evaluate vididencel to support treatment-free remission (TFR) in patients with a previously failed TFR attempt. Mendus and academic collaborators from the Bergen University Hospital will present the initial immune data from the VITAL-CML trial during the 68th American Society of Hematology conference. The abstract titled “Single-cell immune and signaling profiling of vididencel immunotherapy in chronic phase CML” will be presented during Poster Session 631: Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational, held 6-8pm CST on December 13, 2026.